What is ChromaCode?
ChromaCode operates at the intersection of genomics and clinical diagnostics, specializing in High-Definition PCR (HDPCR) multiplexing technology. The company's core value proposition lies in its ability to simplify complex data analysis, thereby enabling laboratories and healthcare providers to access critical molecular insights with greater speed and affordability. By offering a scalable alternative to traditional, more resource-intensive methods, ChromaCode facilitates enhanced molecular profiling, which is essential for precision medicine applications such as tumor profiling and longitudinal disease monitoring.
The company's platform is engineered to support high-margin operations for its lab partners, effectively lowering the barrier to entry for advanced genomic testing. Through its customizable assay solutions, ChromaCode is positioned to address the growing demand for rapid, reliable, and actionable diagnostic data, ultimately aiming to improve patient outcomes through more informed clinical decision-making.
How much funding has ChromaCode raised?
ChromaCode has raised a total of $50M across 2 funding rounds:
Series B
$12M
Series C
$38M
Series B (2017): $12M with participation from Domain Associates and New Enterprise Associates
Series C (2020): $38M led by Adjuvant Capital, Moore Venture Partners, Northpond Ventures, New Enterprise Associates, Domain Associates, Okapi Venture Capital, Windham Ventures, and California Institute of Technology
Key Investors in ChromaCode
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments. It manages nine subsequent biotech venture capital funds and has a total of $2.8 billion in assets.
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a venture capital firm focused on helping entrepreneurs build businesses.
Moore Venture Partners
Founded in 2010, Moore Venture Partners is a traditional venture capital firm that focuses on investing in early, growth, and expansion-stage technology and life science companies.
What's next for ChromaCode?
With the support of its latest financing, ChromaCode is well-positioned to accelerate the commercial deployment of its HDPCR platform. The strategic focus will likely shift toward deepening market penetration in oncology and expanding the utility of its diagnostic assays across broader therapeutic areas. As the company scales, it will likely prioritize the optimization of its supply chain and the enhancement of its digital infrastructure to maintain the high turnaround times that define its competitive advantage.
Furthermore, the company is expected to leverage its strong investor network to explore potential strategic partnerships and clinical collaborations. By maintaining its focus on innovation and operational efficiency, ChromaCode is poised to navigate the complexities of the diagnostic market, aiming to set new standards for accessibility and precision in genomic healthcare.
